Medical Developments International Ltd (ASX: MVP) Share Price and News
Price
–
Movement
– ( )
(20 mins delayed)
52 Week Range
– - –
1 Year Return
Medical Developments International Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
–
Day Change
– ( )
52 Week Range
– - –
Yesterday's Close
–
Today's Open
–
Days Range
– - –
Volume
–
Avg. Volume (1 month)
–
Turnover
–
Medical Developments International Ltd (ASX: MVP)
Latest News
Index investing
Is it time to buy Vanguard Australian Share ETF?
Healthcare Shares
2 ASX biotech shares that could be the next CSL
Coronavirus News
Here's why analysts rate this ASX biotech share a 'buy'
TMF AMP
Top ASX Stock Picks for April 2020
Share Gainers
This small cap ASX healthcare share is racing higher following a coronavirus update
Share Market News
Why this ASX healthcare share has risen over 200% in the past year
Share Market News
Is now the time to buy ASX biotech shares?
Share Fallers
Medical Developments International share price lower on shock CEO exit
Share Market News
What do P/E ratios really mean? And do they matter?
Share Market News
Why are Medical Developments shares crashing 11% lower today?
Share Market News
Medical Developments shares move higher on strong earnings release
Share Market News
3 ASX healthcare growth shares to add to your 2020 watchlist
Frequently Asked Questions
-
Medical Developments International has not paid a Dividend since 2019.
-
Medical Developments International Ltd listed on the ASX on 15 December 2003.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
05 Mar 2020 | $0.0200 | 100.00% | Interim | 17 Apr 2020 |
03 Sep 2019 | $0.0200 | 100.00% | Final | 04 Oct 2019 |
07 Mar 2019 | $0.0200 | 100.00% | Interim | 17 Apr 2019 |
30 Aug 2018 | $0.0200 | 100.00% | Final | 05 Oct 2018 |
02 Mar 2018 | $0.0200 | 100.00% | Interim | 13 Apr 2018 |
31 Aug 2017 | $0.0000 | 100.00% | Final | 06 Oct 2017 |
03 Mar 2017 | $0.0200 | 100.00% | Interim | 10 Apr 2017 |
01 Sep 2016 | $0.0200 | 100.00% | Final | 07 Oct 2016 |
02 Mar 2016 | $0.0200 | 100.00% | Interim | 08 Apr 2016 |
02 Sep 2013 | $0.0200 | 100.00% | Final | 11 Oct 2013 |
27 Feb 2013 | $0.0300 | 100.00% | Interim | 11 Apr 2013 |
28 Feb 2012 | $0.0300 | 100.00% | Interim | 11 Apr 2012 |
31 Aug 2011 | $0.0300 | 100.00% | Final | 10 Oct 2011 |
MVP ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|
About Medical Developments International Ltd
Medical Developments International Ltd (ASX: MVP) is an Australian- based pharmaceutical company. It manufactures and distributes pharmaceutical drugs covering pain management, asthma, and resuscitation, as well as medical and veterinary equipment.
The company has three business units: pharmaceuticals, medical devices, and veterinary products. The majority of its revenue comes from its pharmaceuticals segment which produces and sells the pain relief drug Penthrox within Australia, New Zealand, and the United Kingdom, as well as some sales in other countries.
MVP Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
09 May 2025 | $0.64 | $0.02 | 3.23% | 116,752 | $0.62 | $0.65 | $0.62 |
08 May 2025 | $0.62 | $0.00 | 0.00% | 25,734 | $0.61 | $0.62 | $0.61 |
07 May 2025 | $0.62 | $0.00 | 0.00% | 157,502 | $0.63 | $0.63 | $0.59 |
06 May 2025 | $0.62 | $0.01 | 1.63% | 161,994 | $0.61 | $0.63 | $0.59 |
05 May 2025 | $0.62 | $-0.03 | -4.69% | 159,031 | $0.63 | $0.67 | $0.60 |
02 May 2025 | $0.64 | $0.07 | 12.28% | 324,457 | $0.60 | $0.65 | $0.59 |
01 May 2025 | $0.57 | $-0.03 | -5.00% | 259,972 | $0.60 | $0.62 | $0.56 |
30 Apr 2025 | $0.60 | $-0.01 | -1.64% | 645,492 | $0.62 | $0.64 | $0.53 |
29 Apr 2025 | $0.61 | $0.15 | 32.26% | 1,485,471 | $0.51 | $0.74 | $0.51 |
28 Apr 2025 | $0.47 | $0.01 | 2.20% | 226,188 | $0.45 | $0.50 | $0.45 |
24 Apr 2025 | $0.46 | $0.00 | 0.00% | 72,902 | $0.45 | $0.47 | $0.43 |
23 Apr 2025 | $0.46 | $0.03 | 7.06% | 132,243 | $0.43 | $0.46 | $0.43 |
22 Apr 2025 | $0.43 | $-0.03 | -6.67% | 183,746 | $0.45 | $0.45 | $0.42 |
17 Apr 2025 | $0.45 | $-0.02 | -4.30% | 97,423 | $0.47 | $0.48 | $0.45 |
16 Apr 2025 | $0.47 | $-0.02 | -4.12% | 55,648 | $0.49 | $0.49 | $0.47 |
15 Apr 2025 | $0.49 | $0.01 | 2.08% | 116,522 | $0.49 | $0.51 | $0.46 |
14 Apr 2025 | $0.48 | $-0.02 | -4.00% | 147,097 | $0.48 | $0.48 | $0.45 |
11 Apr 2025 | $0.50 | $0.03 | 6.32% | 33,423 | $0.46 | $0.50 | $0.46 |
10 Apr 2025 | $0.48 | $0.02 | 4.40% | 246,964 | $0.47 | $0.52 | $0.46 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
28 Aug 2024 | Christine Emmanuel-Donnelly | Buy | 26,478 | $10,061 |
As advised by the company. Participation in capital Raise
|
28 Aug 2024 | Gordon Naylor | Issued | 264,782 | $100,617 |
Rights issue.
|
06 Aug 2024 | Leon Hoare | Buy | 8,436 | $3,205 |
As advised by the company. Participation in capital Raise
|
06 Aug 2024 | Richard Betts | Buy | 3,181 | $1,208 |
As advised by the company. Participation in capital Raise
|
06 Aug 2024 | Maria (Mary) Sontrop | Buy | 2,801 | $1,064 |
As advised by the company. Participation in capital Raise
|
06 Aug 2024 | Christine Emmanuel-Donnelly | Buy | 7,684 | $2,919 |
As advised by the company. Participation in capital Raise
|
06 Aug 2024 | Gordon Naylor | Buy | 93,453 | $35,512 |
As advised by the company. Participation in capital Raise
|
06 Aug 2024 | Russell Basser | Buy | 2,160 | $820 |
As advised by the company. Participation in capital Raise
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Leon Hoare | Non-Executive Director | Sep 2013 |
Mr Hoare is a commercial leader with expertise across multiple Life Science sectors. Previously, he was Managing Director of Smith & Nephew (S&N) ANZ, one of S&N's largest global subsidiaries outside the USA. He served as President of S&N's Asia Pacific Advanced Wound Management (AWM) business for 5 years and was a member of the Global Executive Management for the AWM Division (as one of three Regional Presidents). In his 24 years with S&N, he also held roles in marketing, divisional and general management. His career has also included a senior role at Bristol-Myers Squibb, and as Vice-Chair of the board of Australia's peak medical device industry body, Medical Technology Association of Australia. Mr Hoare is also the Chair of the Human Resources Committee. He is member of Human Resource Committee.
|
Mr Richard Betts | Non-Executive Director | May 2021 |
Mr Betts is an experienced executive who has held senior roles with ASX listed entities over 25 years. He was previously Chief Financial Officer at Pact Group Holdings Ltd for 6 years. Prior to that he held executive finance and general management roles at Orica Limited. These roles provided Mr Betts with a deep understanding of working in various jurisdictions, including North America, Europe and Asia. Mr Betts has financial and governance experience within international manufacturing environments. Mr Betts is Chair of the Risk and Continuous Disclosure Committee.
|
Ms Christine Emmanuel-Donnelly | Non-Executive Director | May 2020 |
Ms Emmanuel-Donnelly is an experienced IP and business development professional having 35 years of experience locally and internationally. Ms Emmanuel-Donnelly is a former Executive Manager of Business Development and Commercial at the CSIRO, where she led the management of CSIRO's IP team and IP portfolio for 14 years and managed the CSIRO equity portfolio for over 5 years. Prior to this role, Ms Emmanuel-Donnelly was in-house IP Counsel for Unilever in the UK and practised as a patent and trademark attorney for Wilson Gunn (UK), Davies Collison Cave and Griffith Hack in Melbourne. She is member of Risk Committee.
|
Mr Gordon Naylor | Non-Executive DirectorNon-Executive Chairman | Oct 2020 |
Mr Naylor for over 30 years he was a key part of the internationalisation of CSL, holding a range of business and functional leadership roles including Chief Financial Officer. At the time of his retirement from CSL, he was the President of Seqirus where he led the 3-year turnaround of that business into one of the most successful vaccine companies in the world. He is member of Human Resource and Continuous Disclosure Committee.
|
Dr Russell Basser | Non-Executive Director | Aug 2023 |
Dr Basser is a physician, with over 30 years of international medical and biopharmaceutical experience. Dr Basser worked as a medical oncologist in Melbourne prior to joining CSL in 2001. During his 21 years at CSL, he held multiple global executive roles, including Head of Global Clinical Development, Chief Medical Officer and Senior VP of Research and Development for CSL Seqirus. Dr Basser has expertise in international drug and vaccine development and spent several years based in the USA. He is member of Human Resource Committee.
|
Mr Mark Fladrich | Non-Executive Director | Apr 2025 |
Mr Fladrich brings experience to MVP with over 30 years in the pharmaceutical industry. His background includes senior leadership roles at global companies. During his executive career, Mark was most recently Chief Commercial Officer of Grunenthal, a mid-sized privately owned German company specialising in pain management.In his 23 years at AstraZeneca, Mark held several senior roles including Vice President Global Strategic Marketing, Country President roles in Germany, Australia and New Zealand and Regional Head of Southern and Western Europe. Prior to joining AstraZeneca, Mark held various roles at Allergan (now part of AbbVie Inc) and Faulding Pharmaceuticals in Australia. Mark is the Chair of QBiotics, an Australian public unlisted life sciences company. Mark is also a Board Observer and Strategic Advisor at HealthMatch, a Sydney based digital startup matching patients with clinical trials, and Chair of the Strategic Advisory Board for Atacana, a global pharmaceutical and biotech industry consulting firm.
|
Mr Brent MacGregor | Chief Executive Officer | Nov 2020 |
-
|
Ms Tara Eaton | Company SecretaryGeneral Counsel | Aug 2022 |
-
|
A James | CFO |
-
|
|
Brent MacGregor | Chief Executive Officer |
-
|
|
Tara Eaton | Company SecretaryGeneral Counsel |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
J P Morgan Nominees Australia Pty Limited | 10,683,815 | 9.48% |
Citicorp Nominees Pty Limited | 7,576,013 | 6.72% |
HSBC Custody Nominees (Australia) Limited | 6,500,532 | 5.77% |
Lawn Views Pty Ltd <Angela Williams Family A/C> | 5,904,120 | 5.24% |
Moggs Creek Pty Ltd <Moggs Creek Super A/C> | 5,278,615 | 4.69% |
Ubs Nominees Pty Ltd | 4,920,177 | 4.37% |
Netwealth Investments Limited <Wrap Services A/C> | 3,650,550 | 3.24% |
Payne Media Pty Ltd | 2,937,127 | 2.61% |
Mirrabooka Investments Limited | 2,592,084 | 2.30% |
Dr Russell Kay Hancock | 2,120,000 | 1.88% |
HSBC Custody Nominees (Australia) Limited A/C 2 | 1,367,424 | 1.21% |
BNP Paribas Nominees Pty Ltd <Clearstream> | 1,364,260 | 1.21% |
Naylor Stewart Investments Pty Ltd <Naylor Stewart Family A/C> | 1,045,113 | 0.93% |
Kidder Peabody Pty Ltd | 1,042,945 | 0.93% |
Merrill Lynch (Australia) Nominees Pty Limited | 867,848 | 0.77% |
Mr David Williams <William Street A/C> | 861,817 | 0.76% |
Neweconomy Com Au Nominees Pty Limited <900 Account> | 861,039 | 0.76% |
Mr Alistair David Strong | 750,000 | 0.67% |
National Nominees Limited | 748,009 | 0.66% |
BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 733,300 | 0.65% |